Docosahexaenoic Acid (DHA) (Synonyms: Single-Use Cervonic Acid (peroxide free), Single-Use DHA (peroxide free)) |
| Catalog No.GC30765 |
Docosahexaenoic acid (DHA) is a long-chain polyunsaturated fatty acid with activities in both infants and adults.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 6217-54-5
Sample solution is provided at 25 µL, 10mM.
Docosahexaenoic acid (DHA) is a long-chain polyunsaturated fatty acid with activities in both infants and adults [1]. Docosahexaenoic acid (DHA) is a structural constituent of membranes specifically in the central nervous system. Data from cell and animal studies justify the indication of DHA in relation to brain function for neuronal cell growth and differentiation as well as in relation to neuronal signaling [2].
Docosahexaenoic acid (10-30 µM 48 h) treatment induced apoptosis in three colon cancer cell lines (HT-29, HCT116 and SW480), and inhibited their total and surface GRP78 expression. The cell ability to undergo DHA-induced apoptosis was inversely related to their level of GRP78 expression [3]. Doxorubicin chemosensitization of breast cancer cell lines by docosahexaenoic acid was cell-line selective, affecting MDA-MB-231 and MCF-7dox (a doxorubicin-resistant cell line) but not the parental MCF-7 cell line [4].
Intravenous perioperative treatment with DHA (500 µg), resolvin D1 (RvD1, 500 ng) and maresin 1 (MaR1, 500 ng), 10 min and 24 h after the surgery, delayed the development of fPOP (mechanical allodynia and cold allodynia) in a mouse model of post-operative pain induced by tibial bone fracture [5]. Oral administration of DHA to normal adult mice as lysophosphatidylcholine (LPC) (40 mg DHA/kg) for 30 days increased DHA content of the brain by >2-fold. In contrast, the same amount of free DHA did not increase brain DHA, but increased the DHA in adipose tissue and heart [6]. Supplementation of the high-fat diet with either EPA, DPA or DHA prevented the fatty liver, prevented high serum cholesterol and serum glucose and prevented high liver cholesterol levels [7].
References:
[1]. Lien E L. Toxicology and safety of DHA[J]. Prostaglandins, leukotrienes and essential fatty acids, 2009, 81(2-3): 125-132.
[2]. Lauritzen L, Brambilla P, Mazzocchi A, et al. DHA effects in brain development and function[J]. Nutrients, 2016, 8(1): 6.
[3]. Fasano E, Serini S, Piccioni E, et al. DHA induces apoptosis by altering the expression and cellular location of GRP78 in colon cancer cell lines[J]. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2012, 1822(11): 1762-1772.
[4]. Maheo K, Vibet S, Steghens J P, et al. Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation[J]. Free Radical Biology and Medicine, 2005, 39(6): 742-751.
[5]. Zhang L, Terrando N, Xu Z Z, et al. Distinct analgesic actions of DHA and DHA-derived specialized pro-resolving mediators on post-operative pain after bone fracture in mice[J]. Frontiers in pharmacology, 2018, 9: 412.
[6]. Sugasini D, Thomas R, Yalagala P C R, et al. Dietary docosahexaenoic acid (DHA) as lysophosphatidylcholine, but not as free acid, enriches brain DHA and improves memory in adult mice[J]. Scientific Reports, 2017, 7(1): 1-11.
[7]. Guo X, Sinclair A J, Kaur G, et al. Differential effects of EPA, DPA and DHA on cardio-metabolic risk factors in high-fat diet fed mice[J]. Prostaglandins, Leukotrienes and Essential Fatty Acids, 2018, 136: 47-55.
| Cell experiment [1]: | |
|
Cell lines |
HT-29, HCT116 and SW480 colon cancer cells |
|
Preparation Method |
HT-29, HCT116 and SW480 colon cancer cells were exposed to Docosahexaenoic acid (DHA) (10-30 µM) for 48 h, and apoptosis was morphologically evaluated after acridine-orange staining. |
|
Reaction Conditions |
10-30 µM for 48 hours |
|
Applications |
A much larger fraction of SW480 cells (about 60% with 30 µM DHA) underwent DHA-induced apoptosis than the HCT116 or HT-29 cells (about 15-18% with 30 µM DHA), and that was related to the greater basal propensity for apoptosis of the SW480 cells. |
| Animal experiment [2]: | |
|
Animal models |
Adult CD1 mice (male, 25-35 g) |
|
Preparation Method |
Muscles were disassociated following an incision on the left hind paw. A 0.38-mm stainless steel pin was inserted into the tibia intramedullary canal, followed by the osteotomy. The incision was sutured with 6-0 Prolene. For perioperative treatment, Docosahexaenoic acid (500 µg, 100 µl) or SPMs (500 ng, 100 µl) were dissolved in 2% ethanol as vehicle and administered intravenously through tail vein injection at 10 min and 24 h after surgery. |
|
Dosage form |
500 µg, 100 µl, iv. |
|
Applications |
Intravenous injections of DHA (500 µg, 100 µl) significantly attenuated mechanical allodynia by decreasing paw withdrawal frequency. Compared to vehicle control, cold allodynia was not significantly reduced by DHA. Cold allodynia in the treatment group was also not significantly different from sham surgery, suggesting a possible inhibition of cold allodynia by the DHA pre-treatment. |
|
References: |
|
| Cas No. | 6217-54-5 | SDF | |
| Synonyms | Single-Use Cervonic Acid (peroxide free), Single-Use DHA (peroxide free) | ||
| Canonical SMILES | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(O)=O | ||
| Formula | C22H32O2 | M.Wt | 328.49 |
| Solubility | Ethanol : 50 mg/mL (152.21 mM);DMSO : 5.2 mg/mL (15.83 mM);Water : < 0.1 mg/mL (insoluble) | Storage | Store at -20°C, protect from light, stored under nitrogen |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0442 mL | 15.2212 mL | 30.4423 mL |
| 5 mM | 0.6088 mL | 3.0442 mL | 6.0885 mL |
| 10 mM | 0.3044 mL | 1.5221 mL | 3.0442 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 16 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *